GlycoNex (醣聯) announced on the 6th that it has commissioned the computational simulation team at PrecisemAb Biotech (碩準生技) to utilize high-performance AI and quantum mechanics (QM) modeling for antibody design. This initiative aims to optimize antibody-glycan interaction specificity and develop novel antibodies with superior tumor selectivity.

Technical Evolution:

• From 3D to Quantum: Moving beyond traditional 3D structural simulations, the new platform employs atomic-level calculations to predict electron distribution and binding energy between antibodies and tumor glycan antigens.
• Precision Targeting: By screening candidates at the design source, GlycoNex aims to minimize "off-target" effects on normal tissues, thereby enhancing drug safety.
• CMC Optimization: General Manager Yang Mei-chun noted that AI is also being evaluated for Chemistry, Manufacturing, and Controls (CMC) development to explore process parameters and correlation analysis, effectively shortening development cycles and reducing costs.

Resource: 醣聯導入高階AI算力與模型 加速新一代抗醣抗體開發